Table 6 Estimated true number of cases and prevalence, by stage, project and overall
Project | Estimated number of cases (95% confidence interval) | Prevalence in% (95% confidence interval) | |||
|---|---|---|---|---|---|
Observed | True cases among observed | True cases overall | Observed† | True‡ | |
Kiri | |||||
stage 1 | 114 | 135, 143 (127–158) | 177, 315 (255–388) | 0.23 | 0.31, 0.56 (0.45-0.69) |
stage 2 | 107 | 86, 71 (55–86) | 86, 189 (145–257) | 0.22 | 0.15, 0.33 (0.26-0.45) |
Total | 221 | 221, 214 (207–219) | 263, 507 (429–608) | 0.45 | 0.46, 0.90 (0.76-1.07) |
Adjumani | |||||
stage 1 | 692 | 868, 913 (863–963) | 1129, 1628 (1485–1775) | 0.44 | 0.38, 0.54 (0.49-0.59) |
stage 2 | 727 | 551, 463 (410–513) | 648, 993 (872–1128) | 0.46 | 0.22, 0.33 (0.29-0.38) |
Total | 1419 | 1419, 1375 (1360–1389) | 1777, 2618 (2436–2811) | 0.90 | 0.59, 0.87 (0.81-0.94) |
Arua-Yumbe | |||||
stage 1 | 327 | 404, 392 (366–417) | 495, 624 (564–693) | 0.12 | 0.14, 0.17 (0.15-0.19) |
stage 2 | 243 | 166, 135 (109–162) | 153, 262 (214–321) | 0.09 | 0.04, 0.07 (0.06-0.09) |
Total | 570 | 570, 527 (510–540) | 648, 888 (816–974) | 0.21 | 0.18, 0.24 (0.22-0.27) |